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12 (25 ± 15 nmol l−1) compared with baseline. Despite 
marked increases in total serum 25[OH]D in VItD and a 
decrease in PlB, there were no significant changes in any 
of the muscle function outcome measures at week 6 or 12 
for either group (P > 0.05).
Conclusions Elevating total serum 25[OH]D to con-
centrations > 120 nmol l−1 has no effect on skeletal 
muscle function. We postulate that skeletal muscle func-
tion is only perturbed in conditions of severe deficiency 
(<12.5 nmol l−1).
Keywords cholecalciferol · 25-Hydroxyvitamin D ·  
Supplementation · Isokinetic dynamometry · 
Electromyostimulation · Fatigue
Abbreviations
25[OH]D  25-Hydroxyvitamin D
1,25[OH]D  1,25-Dihydroxyvitamin
ca2+   calcium, Ionized
EclIA   Enzyme-linked chemiluminescent 
immunosorbent assay
EMS   Electromyostimulation
FDA   Food and Drug Agency
iPtH   Intact parathyroid hormone
IU   International units
IKD   Isokinetic dynamometry
lc–MS/MS  liquid chromatography tandem mass 
spectrometry
llOQ   lower limit of quantification
n    newtons
nm   newton metres
nmol l−1  nanomoles per litre
PAr-Q  Physical activity readiness Questionnaire
Pmol l−1  Picomoles per litre
rad s−1   radians per second
Abstract 
Purpose Vitamin D may be a regulator of skeletal muscle 
function, although human trials investigating this hypoth-
esis are limited to predominantly elderly populations. We 
aimed to assess the effect of oral vitamin D3 in healthy 
young males upon skeletal muscle function.
Methods Participants (n = 29) received an oral dose of 
10,000 IU day−1 vitamin D3 (VItD) or a visually identical 
placebo (PlB) for 3 months. Serum 25[OH]D and intact 
parathyroid hormone (iPtH) were measured at baseline 
and at week 4, 8 and 12. Muscle function was assessed in 
n = 22 participants by isokinetic dynamometry and percu-
taneous isometric electromyostimulation at baseline and at 
week 6 and 12.
Results Baseline mean total serum 25[OH]D was 
40 ± 17 and 41 ± 20 nmol l−1 for PlB and VItD, respec-
tively. VItD showed a significant improvement in total 
25[OH]D at week 4 (150 ± 31 nmol l−1) that remained 
elevated throughout the trial (P < 0.005). contrastingly, 
PlB showed a significant decrease in 25[OH]D at week 
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rDI    recommended daily intake
US IoM    United States Institute of Medicine
UVB    Ultraviolet B
Introduction
Vitamin D is classically regarded as a vital endocrine regu-
lator of bone health via its role in calcium and phosphate 
homeostasis (Anderson et al. 2012). However, a myriad of 
non-skeletal effects of the steroid hormone are now known 
and are predominantly attributable to the identification of 
the vitamin D receptor in virtually all tissues (rosen et al. 
2012) including skeletal muscle (Srikuea et al. 2012). 
genome-wide analyses suggest that any improvement in 
vitamin D status significantly affects the expression of a 
large number of genes that have many biological func-
tions (Hossein-nezhad et al. 2013). Specifically regarding 
skeletal muscle, it has long been understood that patients 
with osteomalacia resultant from inadequate dietary vita-
min D intake often display an accompanying skeletal mus-
cle myopathy presenting as a proximal muscle weakness 
that is responsive to vitamin D supplementation (Ziam-
baras and Dagogo-Jack 1997; Irani 1976; Smith and Stern 
1967; Al-Said et al. 2009). Emerging data now suggest at 
a cellular level that skeletal muscle is indeed a tissue that 
responds functionally to vitamin D. recent data have dem-
onstrated in vivo improvements in mitochondrial oxidative 
function when severe vitamin D deficiency is corrected 
in humans (Sinha et al. 2013). Moreover, studies in chick 
embryo myoblast cultures have provided robust evidence 
that vitamin D is a regulator of intracellular ca2+ concen-
tration (capiati et al. 2000; Morelli et al. 1993), which 
has also been observed in vivo in chicks (Vazquez et al. 
1995) and in vitro in fully differentiated soleus muscle (de 
Boland et al. 1988). Vitamin D may therefore be impli-
cated in skeletal muscle contractility, which early reports 
from vitamin D depleted rats have alluded to (rodman 
and Baker 1978). Aside from these observations, reports 
suggest a role for the bioactive vitamin D compound 
1,25-dihydroxyvitamin D (or 1,25[OH]D) in signalling 
pathways which involved myoblast proliferation and dif-
ferentiation indicating a key role for vitamin D in muscle 
cell development and survival (garcia et al. 2013; Srikuea 
et al. 2012; Stratos et al. 2013). Despite such evidence, 
vitamin D deficiency is still widespread around the globe 
(van Schoor and lips 2011). We have previously shown 
that this observation is consistent in sub-populations of 
professional athletes and healthy, young athletic cohorts 
(Morton et al. 2012; close et al. 2013a, b).
A number of trials have sought to assess the effect of 
vitamin D status on muscle function at a macroscopic scale. 
Insights from these investigations have established a link 
between vitamin D status and falls and various other physi-
cal performance measures such as handgrip, lower limb 
strength, balance and gait speed (Bischoff-Ferrari et al. 
2004; gerdhem et al. 2005; Houston et al. 2007; Marantes 
et al. 2011). However, such trials are limited to predomi-
nantly geriatric or clinical populations, and it is difficult 
to generalise such findings to young healthy populations, 
due to age-related skeletal muscle disease (i.e. sarcopenia). 
the few trials that have been conducted in young otherwise 
healthy cohorts have resulted in equivocal findings, with 
some investigations reporting beneficial effects of vitamin 
D supplementation in muscle (Sinha et al. 2013; close 
et al. 2013b) and others observing no perceptible changes 
following supplementation (close et al. 2013a). Hamper-
ing such findings further is large heterogeneity in outcome 
measures implemented to assess muscle function, low par-
ticipant numbers, heterogeneity in supplementation proto-
cols and varying baseline vitamin D status of the sample 
population making the cross comparison between findings 
difficult.
Adding further complexity to this issue is that the daily 
requirement for vitamin D needed to elevate total serum 
vitamin D concentrations to a level necessary for optimal 
physiological function is a point of debate. With regard 
to dose, the United States Institute of Medicine (US IoM) 
has set the rDI for vitamin D at 600 IU day−1 for young 
adults and tolerable upper intake at 4,000 IU day−1 (IoM 
2011), although the US IoM set the ‘no observed adverse 
effect limit’ (nOAEl) at 10,000 IU day−1 (IoM 2011). In 
relation to total serum 25-hydroxyvitamin D (or 25[OH]
D) concentration, the US IoM suggest >50 nmol l−1 as 
adequate whilst suggesting that concentrations exceeding 
125 nmol l−1 may be detrimental to health. Others have 
suggested that these guidelines are too conservative and 
claim values exhibited in those living outdoors in sun-rich 
climates (~100 nmol l−1) to be adequate, since they reflect 
the values present when the human genome evolved in such 
rich environments around equatorial Africa (Vieth 2011; 
Heaney 2011). An ‘optimal’ 25[OH]D concentration for 
muscle function is currently still elusive and no study till 
date has tested the hypothesis that elevating serum 25[OH]
D concentrations to >120 nmol l−1 is optimal for muscle 
function in healthy recreationally active individuals, as 
previously suggested (Heaney 2011). Our group has previ-
ously implemented doses of 20,000 and 40,000 IU week−1 
oral vitamin D3, but failed to elevate serum concentrations 
>100 nmol l−1 (close et al. 2013a). thus higher doses may 
be necessary to achieve a total serum 25[OH]D concentra-
tion >100 nmol l−1.
given the available evidence and a clear lack of data 
in the area, we sought to investigate the impact of vita-
min D status on lower limb muscle function using valid 
macroscopic techniques including percutaneous isometric 
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myostimulation (IMS) and isokinetic dynamometry (IKD) 
in healthy, recreationally active young men. We hypoth-
esized that supplementing with high dose oral vitamin 
D3 (cholecalciferol) to elevate total serum 25[OH]D con-
centrations > 100 nmol l−1 (suggested optimal Zitter-
mann 2003; Heaney 2011; Vieth 2011) would have a ben-
eficial effect on our chosen outcome measures of muscle 
function.
Methodology
Participants
twenty-nine male participants (age = 22.7 ± 3 years; 
height = 179.3 ± 5.9 cm; weight = 76.1 ± 16.2 kg) vol-
unteered to partake in the current trial. Participants received 
detailed information regarding the study procedures and 
were required to complete a PAr-Q, a medical history 
questionnaire and provide written informed consent before 
inclusion in the trial. Strict exclusion criteria were imple-
mented for participant safety and validity of the investi-
gation. Participants were excluded if they had underlying 
health problems as identified by completion of the medical 
history questionnaire, were sunbed users or taking vitamin 
D supplementation, standard oral multivitamins or, cur-
rently unfit to perform physical exercise, currently taking 
prescribed medication and those who expected a drastic 
change in their physical activity/training routine during 
the trial. After meeting these initial inclusion criteria, par-
ticipants provided a venous blood sample that was analysed 
for total 25-hydroxyvitamin D (25[OH]D) concentration. 
those presenting with total serum 25[OH]D concentra-
tions ≥100 nmol l−1 were excluded from the trial. Ethical 
approval was granted by the local ethics committee of liv-
erpool John Moores University, and all data were collected 
in accordance with the Declaration of Helsinki.
Participants were block randomized based on their 
baseline 25[OH]D concentration and electrically evoked 
20 Hz isometric knee extensor force into two experimental 
groups. Of the 29 initial participants, 22 completed all test 
procedures whilst the remaining 6 only took part in supple-
mentation and blood sampling and one dropped out. this 
was due to an inability on the participants’ behalf to com-
mit sufficient time for each testing point. Fourteen partici-
pants were assigned to an oral vitamin D treatment group 
(VItD) and 15 participants were initially assigned to a vis-
ually identical placebo control group (PlB) (see table 1).
Vitamin D supplementation
Participants allocated to VItD received 10,000 IU day−1 
of vitamin D3 (Bio-tech Pharmacal. Arkansas, USA) taken 
as two 5,000 IU gelatin capsules. those allocated to PlB 
received two visually identical placebo capsules each 
containing 90 mg cellulose (Bio-tech Pharmacal. Arkan-
sas, USA). the supplementation period lasted 12 weeks 
between the months of January and April to achieve a pla-
teau in serum 25[OH]D response, as previously shown in a 
dose response trial with 10,000 IU day−1 vitamin D3 chole-
calciferol (Heaney et al. 2003). Both researcher and partici-
pant were blinded until completion of the study procedures.
Blood sampling
For the analysis of vitamin D metabolites and iPtH, par-
ticipants provided a fasted venous blood sample collected 
from the antecubital vein into two K2EDtA plasma (10 ml) 
vacutainers and two serum separator [(SSt) 8.5 ml] vacu-
tainers (Beckton Dickinson. Oxford, UK) prior to supple-
mentation and then at 4, 8 and 12 weeks post-supplemen-
tation. SSt samples were allowed to clot for 1 h at room 
temperature whilst K2EDtA samples were immediately 
stored on ice, following which all samples were centrifuged 
for 15 min at 1,500 rcf at 4 °c. Serum and plasma were 
extracted and stored at −80 °c until required for analysis.
Analysis of vitamin D metabolites and intact parathyroid 
hormone (iPtH) concentration
For the analysis of vitamin D concentration 25(OH)D2, 
25(OH)D3 were extracted from serum samples, follow-
ing zinc sulphate protein precipitation, using Isolute c18 
solid phase extraction cartridges. Potential interfering 
compounds were removed by initial elution with 50 % 
methanol followed by elution of the vitamins using 10 % 
tetrahydrofuran in acetonitrile. Dried extracts were recon-
stituted prior to injection into a high performance liquid 
chromatography tandem mass spectrometer (lc–MS/
MS) in the multiple reaction mode. the multiple reac-
tion mode transitions (m/z) used were 413.2 > 395.3, 
401.1 > 383.3 and, 407.5 > 107.2 for 25(OH)D2, 25(OH)
D3, and hexa-deuterated [OH]D3, respectively. the assay 
Table 1  Block randomization data including mean total serum 
25[OH]D concentration presented as nmol l−1 and mean isometric 
force from a single stimulation at a frequency of 20 Hz and stimula-
tion intensity of 130 mA
PlB VItD
Mean total 25[OH]D (nmol l−1) 40 41
 ±SD 17 21
 t test t = 0.867, P = 0.876
Mean isometric force (n) 267 307
 ±SD 69 67
 t test t = −1.086, P = 0.303
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was validated against published acceptance criteria (FDA 
2001). Assay sensitivity was determined by the lower limit 
of quantification (llOQ): 25[OH]D3 = 2.5 nmol l−1 
and 25[OH]D2 = 2.5 nmol l−1. coefficients of variation 
(cVs) for the assay were 10 % across a working range of 
2.5–625 nmol l−1 for both 25[OH)D2 and 25(OH)D3. Data 
regarding assay precision, detection and recovery are pro-
vided in table 2A, B. table 2A demonstrates imprecision 
of the assay and 2B shows recovery efficiency. Intra-assay 
precision was assessed by running quality control materi-
als (chromsystems Instruments and chemicals. gräfelfing, 
germany) and commercially bought material (calf serum) 
ten times (n = 10) within a single run, and separately over 
15 runs (n = 15) for inter-assay assessment. Values used to 
determine assay variation are expressed as SD and %cV. 
Acceptance criteria define that %cV should not exceed 
10 % in both intra- and inter-assay (table 2A). Extrac-
tion recovery was assessed by determining the amount of 
vitamin D3/D2 recovered from the amount spiked prior to 
extraction. the percentage recovery was calculated by the 
measured value against the sum of endogenous value and 
spiking concentration. Spiked recovery is determined by 
adding known quantity of 25[OH]D3/D2 to serum samples 
with different levels of endogenous 25[OH]D (table 2B). 
the data demonstrate good assay recovery, indicating 
that the procedure was able to efficiently extract vitamin 
D from matrix and the method was able to determine the 
amount recovered accurately. Masscheck calibration mate-
rials and controls are traceable against nISt 972 reference 
material. Furthermore, the lc–MS/MS method of analysis 
has previously been validated against other commercially 
available assays and is regarded as the most valid and reli-
able technique for the assessment of vitamin D metabolites 
(Snellman et al. 2010).
classification of vitamin D status was based upon the 
US IoM (2011) guidelines (see table 3).
For the analysis of iPtH, an Elecsys electrochemilumi-
nescent immunoassay (EclIA) by cobas (roche Diag-
nostics. Indianapolis, USA) was implemented. Fifty μl 
of plasma, a biotinylated monoclonal PtH-specific anti-
body and monoclonal PtH-specific antibody labelled with 
a ruthenium complex were formed into a sandwich com-
plex. After addition of streptavidin-coated microparticles, 
the complex became bound to the solid phase via interac-
tion of biotin and streptavidin. the reaction mixture was 
aspirated into the measuring cell where the microparticles 
Table 2  (A) Imprecision of the lc–MS/MS assay and (B) recovery efficiency of the assay
Intra precision was assessed by running quality control materials (chromsystems) and commercially bought material (calf serum) ten times 
(n = 10) within a single run, and separately over 15 runs (n = 15) for inter-assay assessment. Variation is expressed as standard deviation (SD) 
and percentage of coefficient of variation (%cV)
A
nmol l−1 chromsystem 1 chromsystem 2 calf serum
Vitamin D3 Vitamin D2 Vitamin D3 Vitamin D2 Vitamin D3 Vitamin D2
Intra-assay precision
 Mean 42.9 43.4 80.2 81.1 6.9 7.8
 SD 4.1 3.4 7.8 8.6 0.7 0.8
 %cV 9.5 7.8 9.7 10.6 10.1 10.2
Inter-assay precision
 Mean 40.4 32.4 76.8 95.3 7.7 7.8
 SD 2.4 3.3 7.2 8.3 0.7 0.9
 %cV 6 10 9.3 8.7 9.1 10.8
B
Endogenous 25[OH]D3 (nmol l−1) Spiked (nmol l−1) Measured value (nmol l−1) %recovery
Sample 1 5.5 50 53.7 96.4
Sample 2 10.2 100 103.4 93.8
Blank 0 500 491 98.2
Endogenous 25[OH]D2 (nmol l−1) Spiked (nmol l−1) Measured value (nmol l−1) %recovery
Sample 1 37.0 50 84 96.5
Sample 2 80.2 100 171.3 95
Blank 0 500 479 95.8
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were magnetically captured onto the surface of the elec-
trode. Unbound substances were then removed with Pro-
cell. Application of a voltage to the electrode then induces 
chemiluminescent emission which is measured by a pho-
tomultiplier. results were determined via a calibration 
curve which is instrument-specifically generated by two-
point calibration and a five-point master curve provided 
via the reagent barcode. the measuring range of the assay 
was 0.127–530 pmol l−1 (defined by the lower detection 
limit and the maximum of the master curve). the Elecsys 
EclIA has previously been validated by multicentre evalu-
ation as a valid and reliable measure of iPtH concentration 
(Hermsen et al. 2002).
Assessment of lower limb muscle function
A number of outcome measures were employed to validly 
assess muscle function of the lower limb. Participants com-
pleted both an IKD protocol and EMS protocol. All tests 
were completed at baseline, week 6 and week 12 of sup-
plementation apart from IKD, which was only completed at 
baseline and week 12.
Isokinetic dynamometry
Isokinetic torque was assessed on a Biodex isokinetic 
dynamometer (Biodex Medical Systems Inc. Shirley, nY, 
USA), previously validated for its use in reliable assess-
ment of muscle function variables related to force produc-
tion (Drouin et al. 2004). Participants were seated as per 
the manufacturer’s guidelines with a 90° flexion of the hip 
and non-extendable straps crossing the chest and abdo-
men and across the quadriceps to maximise isolation of the 
target muscle groups. the test protocol consisted of four 
consecutive maximal extension and flexion movements 
(Baltzopoulos and Brodie 1989) of the right quadriceps 
and hamstrings at two different fixed angular velocities, 
1.05 rad s−1 (60 deg s−1) and 3.14 rad s−1 (180 deg s−1) 
from which peak torque (nm) was generated, separated 
by a 5-min rest to allow full recovery of the high energy 
phosphate pool (Soderlund and Hultman 1991). testing at 
two angular velocities produces valuable information as 
to how peak torque is produced by during different activa-
tion patterns (Baltzopoulos and Brodie 1989) as it is under-
stood that neurological activation patterns of motor units 
changes as the angular velocity increases e.g. from 60 to 
180 deg s−1 (lesmes et al. 1978) thus replicating differ-
ent locomotive activities. All participants were familiar-
ized with the protocol until the coefficient of variation for 
each participant was <10 % (Atkinson and nevill 1998) 
(table 4).
Percutaneous isometric electromyostimulation
Stimulation was applied through surface electrodes, deliv-
ered via a BIOPAc systems MP100 stimulator (BIOPAc 
systems inc, Santa Barbara, cA, USA) and knee extension 
forces were recorded with a tension compression load cell 
(tedea-Huntleigh, Vishay Precision group Inc. Malvern, 
PA, USA) connected to a non-extendable strap attached to 
the participants’ lower leg approximately 2–3 inches from 
the malleolus. Information collected from the force trans-
ducer was visualized and analysed using AcqKnowledge 
v.3.7.2 software (BIOPAc systems inc. Santa Barbara, cA, 
USA). Muscles were stimulated at an intensity of 130 mA 
for each test procedure as described previously (gerrits 
et al. 2002). For the determination of muscle contractile 
properties, contraction was evoked by a 1-Hz twitch. For 
the determination of fatigue resistance, contractions were 
evoked by 20 Hz, 200-ms square wave pulses, previously 
defined to be representative of normal voluntary human 
motor neurone firing rates (Bigland-ritchie et al. 1979), 
and thus physiologically valid when used to assess the 
fatigue resistance of human skeletal muscle.
For every session, the position of the participant in the 
isometric chair (lido Active, loredan, Davis, cA, USA) 
was standardized in accordance with guidelines previ-
ously published (Morton et al. 2005). two 3 × 5 inch 
(8 × 13 cm) oval self-adhesive stimulating electrodes 
(chattanooga, DJO global, cA, USA) were placed approx-
imately 2 inches above the knee joint across the vastus 
medialis (VM) and proximal to the acetabulofemoral joint 
across the vastus lateralis (Vl). Participants were required 
to fully extend and contract the quadriceps to make the 
muscle body more apparent prior to electrode placement 
Table 3  the US IoM (2011) guidelines for vitamin D status and 
suggested optimal concentrations (Zittermann 2003)
Serum 25[OH]D (nmol l−1) Status
<12 Severely deficient
12 to <30 Deficient
30 to 50 Inadequate
>50 Adequate
>100 to 250 Suggested optimal (Zittermann 2003)
>120 to 225 Suggested optimal (Heaney 2011)
Table 4  co-efficient of variation for each isokinetic dynamometry 
variable
Data are presented as group means from familiarization trials. 
1.05 rad s−1  = 60 deg s−1; 3.14 rad s−1 = 180 deg s−1
Measurement 
variable
Flexion 
1.05 rad s−1
Extension 
1.05 rad s−1
Flexion 
3.14 rad s−1
Extension 
3.14 rad s−1
cV% 3.9 3.7 4.9 4.1
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to minimise antagonist coactivation, although this was not 
monitored with electromyography during stimulation.
to determine time to peak twitch and half relaxation 
time, a 1-Hz, 200-ms square wave pulse was administered. 
time to peak twitch was determined as the time taken to 
reach peak isometric force from the onset of stimulation. 
Half relaxation time was determined as the time from peak 
stimulated force to reach half peak stimulated force. test–
retest reliability data revealed that the cV % for time to 
peak twitch and for ½ relaxation time as determined by a 
1-Hz twitch at 130 mA was 4.5 and 5.7 %, respectively. 
Fatigue resistance was determined from 2 min repeated 
stimulation with 20 Hz, 200-ms square wave pulses every 
750 ms (total of 160 evoked contractions equating to 32 s 
of total stimulation). Fatigue index was calculated as abso-
lute force loss from the first stimulated contraction to the 
final stimulated contraction.
Statistical methods
A power calculation was performed by a priori using 
Minitab software (v.16) to allow for any dropouts based 
on detecting a significant change in serum 25[OH]D and 
increased peak torque in response to vitamin D supplemen-
tation. Pilot work from our laboratories during the winter 
months suggested that the standard deviation for test–retest 
serum 25[OH]D concentrations (taken 6 weeks apart) in 
young athletes is ∼12 nmol l−1. Furthermore, previous 
work from our laboratory demonstrated that standard devi-
ation in isokinetic force at 1.04 rad s−1 (60 deg s−1) is ~35 
nm. to enable the detection of a 50 nmol l−1 increase in 
total serum 25[OH]D concentration between pre-supple-
mentation and post-supplementation with 80 % power, 
n = 3 participants per group was required. to enable a 
10 % (21 nm) increase in peak torque between pre-sup-
plementation and post-supplementation with 80 % power, 
n = 12 per experimental group was required. therefore, we 
initially recruited 30 participants to allow for dropouts and 
maintain statistical power.
For determination of test–retest reliability in familiariza-
tion trials, a paired sample t test was used. For the analy-
ses of total serum 25[OH]D, PtH and all muscle function 
measurement variables, a two-way mixed design AnOVA 
was implemented. Where an interaction between inde-
pendent variables was detected, simple main effects were 
explored with a one-way AnOVA. Significant main effects 
were explored using the Bonferroni post-hoc procedure and 
α was set at 0.05. In addition, a linear regression was plot-
ted using Pearson’s correlation to assess whether baseline 
25[OH]D concentration was a predictor of Δ 25[OH]D in 
response to supplementation. All analyses were performed 
using SPSS (Predictive Analytics Software v.20, IBM cor-
poration, nY, USA). Data are presented as mean ± SD.
Results
total serum 25[OH]D and iPtH
there was a significant interaction between group and 
time for total serum 25[OH]D (P < 0.005). Serum 25[OH]
D concentration showed a significant main effect for time 
(P < 0.005) and treatment group (P < 0.005). Participants 
in VItD demonstrated significantly elevated total serum 
25[OH]D concentrations at week 4 compared with base-
line that remained elevated throughout the trial. contrast-
ingly, participants in PlB displayed total serum 25[OH]
D concentrations significantly lower at week 12 compared 
with baseline (see Fig. 1a). In addition, regression analysis 
revealed that pre-treatment vitamin D concentration was a 
strong predictor of 25[OH]D response to supplementation 
in VItD, where 83 % of the variation in response to sup-
plementation was attributable to baseline concentration 
(see Fig. 1b). VItD showed no significant change in iPtH 
concentration throughout the trial (P = 0.322), whereas 
PlB showed a significant increase in iPtH concentration 
at week 4 (P < 0.005), which remained elevated throughout 
the trial (see Fig. 1c) showing an inverse relationship with 
serum 25[OH]D.
Maximum voluntary contraction
there were no differences between experimental groups 
in peak torque production at either of the fixed movement 
velocities or for flexion/extension (P = 0.610). Further-
more there was no effect of experimental treatment as no 
changes were observed in peak torque production for either 
of the movement velocities or for flexion/extension fol-
lowing supplementation with 10,000 IU day−1 vitamin D3 
(P = 0.345, see Fig. 2).
Fatigue resistance
the effects of vitamin D supplementation on fatigue resist-
ance of the Vl and VM muscles can be seen in Fig. 3. 
Data are presented as absolute maximal force (Fig. 3a) and 
percentage of maximal force (Fig. 3b), although statisti-
cal analysis was performed on the fatigue ratio of absolute 
data only. no significant interaction was detected between 
treatment group and time i.e. baseline, week 6 and week 12 
(P = 0.134). However, approaching significant main effect 
was also not observed for experimental group (P = 0.063).
time to peak twitch and half relaxation time
no significant differences were detected between treat-
ment groups for time taken to reach peak isometric twitch 
force (P = 0.968) or half relaxation time (P = 0.924). 
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Furthermore, there was no significant effect of time for 
either time to peak twitch (P = 0.861) or half relaxation 
time (P = 0.293) indicating that a treatment effect was not 
observed (see Fig. 4).
Discussion
the aim of the current study was to investigate the impact 
of vitamin D status on muscle function in healthy, recrea-
tionally active young men. We hypothesized that supple-
menting with oral vitamin D3 (cholecalciferol) to elevate 
total serum 25[OH]D concentrations > 100 nmol l−1 (sug-
gested optimal Zittermann 2003; Heaney 2011; Vieth 2011) 
would have a beneficial effect on muscle function. How-
ever, we demonstrate that in a population of predominantly 
vitamin D inadequate young men, supplementation with 
10,000 IU day−1 effectively elevated total serum 25[OH]D 
Fig. 1  a response of total serum 25[OH]D to 12-week supplementa-
tion with 10,000 IU day−1 vitamin D3 or placebo. b linear regression 
describing the relationship between baseline vitamin D status and 
response to supplementation. Baseline total 25[OH]D concentration 
is the predictor variable whilst change in total 25[OH]D at 12 weeks 
is the response variable. c response of intact parathyroid hormone to 
12-week supplementation with 10,000 IU day−1 vitamin D3 or pla-
cebo. (Asterisk) Denotes significance to baseline (P < 0.05)
Fig. 2  Peak torque data from maximal extension (ext) and flexion 
(flex) of the right lower limb at two fixed velocities of 1.05 rad s−1 
(60o s−1) and 3.14 rad s−1 (180o s−1) prior to and following 12-week 
supplementation with 10,000 IU day−1 or placebo
 Eur J Appl Physiol
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concentration to values >100 nmol l−1; this had no effect 
(positive or negative) on muscle force, muscle fatigue or 
muscle contractile properties.
Our primary findings are in agreement with other ran-
domized interventional trials assessing the impact of vita-
min D supplementation on skeletal muscle function. Pre-
vious data from our group has demonstrated in a sample 
of 30 club level athletes with a mean 25[OH]D concen-
tration of 51 nmol l−1 (SD ± 24 nmol l−1) that neither 
20,000 or 40,000 IU week−1 of vitamin D3 for 12 weeks 
were effective in improving 1-rM bench press, leg press 
or vertical jump height, although both doses achieved a 
significant elevation of total serum 25[OH]D (20,000 and 
40,000 IU day−1 vitamin D3 = 85 ± 10 nmol l−1 and 
91 ± 24 nmol l−1, respectively) after 12 weeks (close 
et al. 2013a). Similarly, other studies predominantly under-
taken in elderly cohorts have failed to detect improvements 
in strength parameters following supplementation (Kukul-
jan et al. 2011; Kenny et al. 2003). As highlighted in a sys-
tematic review and meta-analysis, trials in which the sam-
ple population display serum concentrations >25 nmol l−1 
have failed to show improvements in muscle strength 
parameters following supplementation (Stockton et al. 
2011).
We also report that elevating serum 25[OH]
D > 100 nmol l−1 does not negate the force producing 
capacity, fatigue resistance or contractile properties of 
skeletal muscle in humans, an idea that has previously 
Fig. 3  a Absolute isometric 
force and b percentage force 
loss during 120 s of repeated 
unilateral lower limb stimu-
lation from an electrically 
evoked square wave pulse of 
200 ms, 20 Hz and a stimula-
tion intensity of 130 mA, every 
750 ms. Data presented prior to 
supplementation (baseline) and 
then at week 6 and 12 of sup-
plementation
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been suggested; One randomized controlled trial has 
previously reported that annual high dose vitamin D3 
(500,000 IU) effectively elevated serum concentrations of 
25[OH]D to approximately 120 nmol l−1 in community 
dwelling older women (Sanders et al. 2010). However, 
this resulted in an increased risk of falls and fractures 
compared with a placebo control group. this observation 
could be attributable to the dosing strategy implemented, 
as smaller but more frequent doses in other rct’s do not 
show comparable findings. Furthermore, although Sand-
ers et al. state that baseline prevalence of risk factors for 
falls and fractures was similar in both the supplemented 
and placebo groups, the physical activity profile of the 
two experimental groups is not reported. this is a con-
founding factor given that physical activity is a valuable 
counter measure for sarcopenia (Forbes et al. 2012), thus 
disparity in the physical activity profile of the two experi-
mental groups is of importance when interpreting this 
data.
We also report that measurement of iPtH displayed an 
inverse relationship with serum 25[OH]D, in line with pre-
vious data (Sai et al. 2011). PlB showed elevated iPtH 
concentration whereas the opposite was observed for 
VItD, which may be explained by the understanding that 
1,25-dihydroxyvitamin D represses the transcription of 
the PtH gene and also indirectly regulates PtH secretion 
by regulating the expression of calcium sensing receptors 
(Kumar and thompson 2011). thus, in addition to provid-
ing evidence that our findings produce no negative effect 
of high serum 25[OH]D concentrations (>100 nmol l−1) 
on skeletal muscle function, we further demonstrate that 
our supplementation protocol offers a positive effect on 
the maintenance of iPtH concentrations. It is reported 
that high serum 25[OH]D concentrations (>100 nmol l−1) 
may be necessary for disease prevention (Heaney 2011; 
Vieth 2011), thus we demonstrate that such concentrations 
needed to optimise other biological functions are unlikely 
to be detrimental to the normal function of skeletal muscle.
It is important to also consider the available evidence 
that suggests vitamin D supplementation has a beneficial 
impact on muscle function. case studies have previously 
described a proximal muscle weakness associated with 
nutritional osteomalacia that is responsive to supplemen-
tation with vitamin D (Ziambaras and Dagogo-Jack 1997; 
Irani 1976; Smith and Stern 1967; Al-Said et al. 2009). 
recently, in contrast to our current findings, we have 
observed an improvement in 10-m sprint times and verti-
cal jump height following supplementation in a group of 
vitamin D deficient young athletes (close et al. 2013b). A 
recent trial has also demonstrated in a sample of severely 
deficient individuals (all <15 nmol l−1) that supplemen-
tation with 20,000 IU of vitamin D3 on alternate days 
for 10–12 weeks significantly elevated serum 25[OH]
D (>100 nmol l−1) and resulted in significant improve-
ments in phosphocreatine recovery half-time (τ½ Pcr) of 
the soleus muscle, indicative of improved mitochondrial 
oxidative function as measured by 31P-magnetic resonance 
spectroscopy (Sinha et al. 2013). Furthermore, in a system-
atic review previously mentioned (Stockton et al. 2011), 
the authors also discuss that though participants with base-
line 25[OH]D >25 nmol l−1 show no change in muscle 
strength with vitamin D supplementation, a limited num-
ber of trials demonstrate an increase in proximal muscle 
strength in adults with vitamin D deficiency. A common 
underlying feature of these positive outcome trials is that 
a large portion of the sample population exhibited severe 
vitamin D deficiency (<12 nmol l−1) at baseline that was 
corrected with vitamin D3 supplementation. It is reasona-
ble to postulate based on such findings that skeletal muscle 
function only displays perceptible perturbations in function 
when vitamin D status of the sample population reaches 
concentrations <12 nmol l−1.
Fig. 4  Muscle contractile properties from an electrically evoked 
1-Hz twitch and a stimulation intensity of 130 mA. Data are dis-
played from baseline, 6 and 12 weeks of supplementation with 
10,000 IU day−1 vitamin D3 or placebo
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taking the available evidence into account, we propose a 
possible reason that an improvement in muscle function was 
not detected in the current study, because muscle function 
was not impaired to begin with as no participants had serum 
25[OH]D concentrations in the range <12 nmol l−1. If one 
assumes a sigmoidal physiological response of skeletal 
muscle to vitamin D, it may be difficult to detect a response 
when nutrient status is already on the ascending limb or pla-
teau of the response curve (lappe and Heaney 2012). thus 
skeletal muscle may only display sharp decrements in func-
tion at serum 25[OH]D concentrations <12 nmol l−1, but 
thereafter shows no perceptible added benefit of the increas-
ing concentrations. this could be due to a disturbance of 
systemic and intracellular calcium concentrations that occur 
in severe deficiency, affecting both contractile activity and 
intracellular signalling, and a notion previously put for-
ward (girgis et al. 2012). Although speculative, this would 
explain much of the human data available on vitamin D sta-
tus and muscle function.
We acknowledge that there were limitations in the 
current study design regarding supplemental dose and 
response. We did not measure markers of vitamin D tox-
icity thus compromising the efficacy of our supplemen-
tation protocol. An early indication of adverse effects 
to vitamin D supplementation is hypercalciuria (Vieth 
2007); however, this was not monitored in the current trial. 
Symptoms of vitamin D toxicity are wholly attributable 
to hypercalcemia/hypercalciuria, including nausea, dehy-
dration and lethargy. no participants reported any of the 
associated symptoms. the dose of 10,000 IU day−1 was 
selected as previous trials including our own (close et al. 
2013a) have failed to achieve the desired serum 25[OH]D 
concentrations >100 nmol l−1 with lower doses. In addi-
tion, data have demonstrated that oral vitamin D intakes 
of 9,600 IU day−1 are needed to obtain serum 25[OH]
D concentrations above 100 nmol l−1 in 97 % of a large 
cohort of 3,667 participants (garland et al. 2011). clinical 
trial evidence and dermal photosynthesis of vitamin D fol-
lowing UVB exposure supports our assumption that a pro-
longed daily dose of 10,000 IU•day−1 is unlikely to cause 
adverse effects in otherwise healthy persons (Vieth 2007). 
the authors are, however, in support of toxicity monitor-
ing in future trials that employ high daily doses of vitamin 
D. Further, our sample size calculation determined that to 
enable a 10 % (21 nm) increase in peak torque between 
pre-supplementation and post-supplementation with 80 % 
power, n = 24 was required. Although 29 participants 
completed supplementation and blood sampling, only 22 
completed all muscle function trials. this is a potential 
confounding factor, however, it may be argued given that 
no trends were observed, and P-values were strongly non-
significant that it is unlikely a two-participant deficit that 
significantly affected our findings.
Conclusions
In summary, the current investigation has added to a body 
of evidence that suggests young healthy adults present with 
inadequate and deficient vitamin D concentrations in the 
winter months. We have demonstrated that elevating serum 
25[OH]D concentrations in a predominantly insufficient 
group to concentrations >100 nmol l−1 may be effectively 
achieved by daily supplementation with 10,000 IU vitamin 
D3 (cholecalciferol); however, this does not improve or 
negate skeletal muscle function. We propose that muscle 
function of healthy young adults is likely only aberrant in 
a state of severe vitamin D deficiency (<12 nmol l−1) and 
thus future work should assess this. Due to the inter-indi-
vidual variation in baseline vitamin D status and response 
to supplementation, it is crucial that the baseline vitamin D 
concentration of the sample population being tested is con-
sidered in any interventional trial as this may have a signifi-
cant impact upon the outcome of the trial.
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